Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

Oncology Reports

Volumn 32, Issue 6, 2014, Pages 2319-2326

  Tanaka, Nozomu ^a,b   Sakamoto, Kazuki ^a   Okabe, Hiroyuki ^a   Fujioka, Akio ^a   Yamamura, Keisuke ^a   Nakagawa, Fumio ^a   Nagase, Hideki ^a   Yokogawa, Tatsushi ^a   Oguchi, Kei ^a   Ishida, Keiji ^a   Osada, Akiko ^a   Kazuno, Hiromi ^a   Yamada, Yukari ^a   Matsuo, Kenichi ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Lonsurf; TAS 102; Tipiracil hydrochloride; Trifluridine

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; CYTARABINE; DEOXYURIDINE PHOSPHATE; FLOXURIDINE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NUCLEOSIDE ANALOG; TAS 102; THYMIDYLATE SYNTHASE; TIPIRACIL; TRIFLURIDINE; UNCLASSIFIED DRUG; DNA; DRUG COMBINATION; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG COMBINATION; DRUG SCREENING; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA, NEOPLASM; DRUG COMBINATIONS; MALE; MICE, INBRED BALB C; MICE, NUDE; TRIFLURIDINE; URACIL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914671294     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3487     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
3. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study e3200. J Clin Oncol 25: 1539-1544, 2007.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
5. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007.
6. Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319, 2008.
7. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713, 2010.
8. Heidelberger C, Parsons DG and Remy DC: Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2'-deoxyuridine. J Med Chem 7: 1-5, 1964.
9. Fujiwara Y, Oki T and Heidelberger C: Fluorinated pyrimidines. XXXVII. effects of 5-trifluoromethyl-2'-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol 6: 273-280, 1970.
10. Yoshino T, Mizunuma N, Yamazaki K, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13: 993-1001, 2012.
11. Dexter DL, Wolberg WH, Ansfield FJ, Helson L and Heidelberger C: The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. Cancer Res 32: 247-253, 1972.
12. Ansfield FJ and Ramirez G: Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 55: 205-208, 1971.
13. Skevaki CL, Galani IE, Pararas MV, Giannopoulou KP and Tsakris A: Treatment of viral conjunctivitis with antiviral drugs. Drugs 71: 331-347, 2011.
14. Fukushima M, Suzuki N, Emura T, et al: Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol 59: 1227-1236, 2000.
15. Langenbach RJ, Danenberg PV and Heidelberger C: Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate. Biochem Biophys Res Commun 48: 1565-1571, 1972.
16. Miller EM and Kinsella TJ: Radiosensitization by fluorode-oxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 52: 1687-1694, 1992.
17. Sampath D, Rao VA and Plunkett W: Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22: 9063-9074, 2003.
18. Pettersen HS, Visnes T, Vågbø CB, et al: UNg-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res 39: 8430-8444, 2011.
19. Suzuki N, Emura T and Fukushima M: Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes. Int J Oncol 39: 263-270, 2011.
20. Quesada-Soriano I, Casas-Solvas JM, Recio E, et al: Kinetic properties and specificity of trimeric Plasmodium falciparum and human dUTPases. Biochimie 92: 178-186, 2010.
21. Emura T, Nakagawa F, Fujioka A, et al: An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13: 249-255, 2004.
22. Markley JC, Chirakul P, Sologub D and Sigurdsson ST: Incorporation of 2'-deoxy-5-(trifluoromethyl)uridine and 5-cyano-2'-deoxyuridine into DNA. Bioorg Med Chem Lett 11: 2453-2455, 2001.
23. Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M and Kruyt FA: Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 126: 2457-2468, 2010.